Literature DB >> 19499420

A critique of the dopamine hypothesis of schizophrenia and psychosis.

Joanna Moncrieff1.   

Abstract

The dopamine hypothesis of schizophrenia and psychosis originated from observations of the dopamine-blocking actions of early neuroleptic drugs. These results support the dopamine hypothesis, however, only on the assumption that the drugs act by reversing an underlying disease mechanism (or part of it). An alternative explanation is that the drugs work by inducing a state of neurological suppression that reduces the intensity of symptoms. Although stimulant drugs are known to induce episodes of psychosis, the mechanism for stimulant-induced psychosis has not been clarified, and stimulants are known to affect many neurotransmitters other than dopamine. Recent imaging studies suggest that there may be increased dopamine release in response to amphetamine administration compared to controls. Some studies indicate increased uptake of L-dopa in parts of the striatum, but some do not. The potential confounding effects of factors associated with dopamine release--such as movement, arousal, attention, stress, and smoking--have rarely been examined, and prior medication use may also have influenced results in some studies. Comparable research on other psychiatric conditions associated with increased arousal, stress, and physical activity is sparse. Research on dopamine concentrations in postmortem brain tissue, on homovanillic acid concentrations, and on dopamine receptors has been negative or inconclusive. Therefore, the idea that the symptoms of psychosis or schizophrenia are caused by the overactivity of dopamine is not supported by current evidence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499420     DOI: 10.1080/10673220902979896

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  19 in total

Review 1.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 2.  Systems psychopharmacology: A network approach to developing novel therapies.

Authors:  Peter J Gebicke-Haerter
Journal:  World J Psychiatry       Date:  2016-03-22

3.  A118G polymorphism of OPRM1 gene is associated with schizophrenia.

Authors:  Omar Serý; Radovan Prikryl; Lukás Castulík; Frantisek St'astný
Journal:  J Mol Neurosci       Date:  2010-01-29       Impact factor: 3.444

4.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

5.  Nicotine dependence and serum BDNF levels in male patients with schizophrenia.

Authors:  Xiang Yang Zhang; Mei Hong Xiu; Da Chun Chen; Fu De Yang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

6.  Chronic exposure of mutant DISC1 mice to lead produces sex-dependent abnormalities consistent with schizophrenia and related mental disorders: a gene-environment interaction study.

Authors:  Bagrat Abazyan; Jenifer Dziedzic; Kegang Hua; Sofya Abazyan; Chunxia Yang; Susumu Mori; Mikhail V Pletnikov; Tomas R Guilarte
Journal:  Schizophr Bull       Date:  2013-05-28       Impact factor: 9.306

Review 7.  Genetic insights into the neurodevelopmental origins of schizophrenia.

Authors:  Rebecca Birnbaum; Daniel R Weinberger
Journal:  Nat Rev Neurosci       Date:  2017-10-26       Impact factor: 34.870

8.  Research on a 'drug-centred' approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs.

Authors:  J Moncrieff
Journal:  Epidemiol Psychiatr Sci       Date:  2017-10-12       Impact factor: 6.892

9.  Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders.

Authors:  Y Ayhan; B Abazyan; J Nomura; R Kim; B Ladenheim; I N Krasnova; A Sawa; R L Margolis; J L Cadet; S Mori; M W Vogel; C A Ross; M V Pletnikov
Journal:  Mol Psychiatry       Date:  2010-01-05       Impact factor: 15.992

10.  A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression.

Authors:  Jerry Guintivano; Martin J Aryee; Zachary A Kaminsky
Journal:  Epigenetics       Date:  2013-02-20       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.